|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2001-2-2
|
|
pubmed:abstractText |
The outcome of treatment of advanced renal cell carcinoma is disappointing. In interferon (IFN)-treated patients, the high incidence of adverse effects causes many patients to withdraw from treatment. This 12-week randomized study compared the incidence of toxicity associated with high-dose IFN monotherapy (15 x 10(6) U thrice weekly) and treatment with the combination of low-dose IFN (5 x 10(6) U thrice weekly) and 6 mg/m2 vinblastine (VBL) every 14 days in 100 consecutive patients. There was no significant difference in response rate between treatment arms (42% IFN vs. 34% IFN + VBL) or between subgroups (by tumor location). Combined treatment was associated with a significantly lower incidence of fever, fatigue, and weight loss but with a higher incidence of leukopenia. There was no significant difference in the incidence of other events. More patients treated with IFN monotherapy required bed rest, and overall treatment costs were 60% higher than for combined treatment. It is concluded that combined treatment with low-dose IFN and VBL, without loss of short-term efficacy, is better tolerated and less expensive than high-dose IFN monotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1079-9907
|
|
pubmed:author |
pubmed-author:AravantinosGG,
pubmed-author:BacoyiannisCC,
pubmed-author:BougasDD,
pubmed-author:DimitrakopoulosAA,
pubmed-author:KosmasCC,
pubmed-author:KosmidisPP,
pubmed-author:KostantinidisKK,
pubmed-author:MitropoulosDD,
pubmed-author:PanopoulosCC,
pubmed-author:PantazopoulosDD,
pubmed-author:RetalisGG,
pubmed-author:SkarlosDD,
pubmed-author:TsavarisNN,
pubmed-author:VadiakaMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
685-90
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10954911-Adult,
pubmed-meshheading:10954911-Aged,
pubmed-meshheading:10954911-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10954911-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10954911-Carcinoma, Renal Cell,
pubmed-meshheading:10954911-Costs and Cost Analysis,
pubmed-meshheading:10954911-Drug Tolerance,
pubmed-meshheading:10954911-Fatigue,
pubmed-meshheading:10954911-Female,
pubmed-meshheading:10954911-Fever,
pubmed-meshheading:10954911-Humans,
pubmed-meshheading:10954911-Interferon-alpha,
pubmed-meshheading:10954911-Kidney Neoplasms,
pubmed-meshheading:10954911-Leukopenia,
pubmed-meshheading:10954911-Male,
pubmed-meshheading:10954911-Middle Aged,
pubmed-meshheading:10954911-Recombinant Proteins,
pubmed-meshheading:10954911-Vinblastine,
pubmed-meshheading:10954911-Weight Loss
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
|
|
pubmed:affiliation |
Department of Pathophysiology, Laiko General Hospital, University of Athens, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
